2X 121

Drug Profile

2X 121

Alternative Names: 2X-121; E-7449

Latest Information Update: 08 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Eisai Co Ltd
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Poly(ADP-ribose) polymerase inhibitors; Tankyrase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II B cell lymphoma; Solid tumours

Most Recent Events

  • 08 Aug 2017 Chemical structure information added
  • 01 Aug 2017 Efficacy data from a Clinical study in Cancer released by Oncology Venture
  • 07 Jul 2017 E7449 licensed to 2X Oncology worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top